Alzheimer’s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment

Mild-cognitive impairment (MCI) occurs in up to one-fifth of individuals over the age of 65, with approximately a third of MCI individuals converting to dementia in later life. There is a growing necessity for early identification for those at risk of dementia as pathological processes begin decades before onset of symptoms. A cohort of 122 individuals diagnosed with MCI and followed up for a 36-month period for conversion to late-onset Alzheimer’s disease (LOAD) were genotyped on the NeuroChip array along with pathologically confirmed cases of LOAD and cognitively normal controls. Polygenic risk scores (PRS) for each individual were generated using PRSice-2, derived from summary statistics produced from the International Genomics of Alzheimer’s Disease Project (IGAP) genome-wide association study. Predictability models for LOAD were developed incorporating the PRS with APOE SNPs (rs7412 and rs429358), age and gender. This model was subsequently applied to the MCI cohort to determine whether it could be used to predict conversion from MCI to LOAD. The PRS model for LOAD using area under the precision-recall curve (AUPRC) calculated a predictability for LOAD of 82.5%. When applied to the MCI cohort predictability for conversion from MCI to LOAD was 61.0%. Increases in average PRS scores across diagnosis group were observed with one-way ANOVA suggesting significant differences in PRS between the groups (p < 0.0001). This analysis suggests that the PRS model for LOAD can be used to identify individuals with MCI at risk of conversion to LOAD.

[1]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[2]  A. Mitchell,et al.  Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies , 2009, Acta psychiatrica Scandinavica.

[3]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[4]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[5]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[6]  R. Buckner,et al.  The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. , 2012, Cerebral cortex.

[7]  O. Combarros,et al.  Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer’s disease , 2013, Journal of Neural Transmission.

[8]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[9]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[10]  C. Reitz,et al.  Genome-wide Association Studies in Alzheimer’s Disease: A Review , 2013, Current Neurology and Neuroscience Reports.

[11]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[12]  Benjamin F. J. Verhaaren,et al.  Alzheimer's Disease Genes and Cognition in the Nondemented General Population , 2013, Biological Psychiatry.

[13]  C. Holmes,et al.  Systemic inflammatory responses to stress and its impact on cognition in people with mild cognitive impairment , 2013, Alzheimer's & Dementia.

[14]  P. Deyn,et al.  A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42 , 2015, Alzheimer's & Dementia.

[15]  A. Hofman,et al.  Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia , 2015, Alzheimer's & Dementia.

[16]  M. Gill,et al.  Common polygenic variation enhances risk prediction for Alzheimer's disease. , 2015, Brain : a journal of neurology.

[17]  B. Miller,et al.  Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer’s disease , 2015, BMC Neurology.

[18]  Jens Keilwagen,et al.  PRROC: computing and visualizing precision-recall and receiver operating characteristic curves in R , 2015, Bioinform..

[19]  Takaya Saito,et al.  The Precision-Recall Plot Is More Informative than the ROC Plot When Evaluating Binary Classifiers on Imbalanced Datasets , 2015, PloS one.

[20]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[21]  V. Pankratz,et al.  Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease , 2015, Neurobiology of Aging.

[22]  T. Lehtimäki,et al.  Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach. , 2014, Journal of Alzheimer's disease : JAD.

[23]  Jianfeng Xu,et al.  Risk prediction for sporadic Alzheimer's disease using genetic risk score in the Han Chinese population , 2015, Oncotarget.

[24]  Jack Euesden,et al.  PRSice: Polygenic Risk Score software , 2014, Bioinform..

[25]  I. Kawachi,et al.  Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up , 2016, Alzheimer disease and associated disorders.

[26]  A. Ruiz,et al.  Genome research in pre-dementia stages of Alzheimer's disease , 2016, Expert Reviews in Molecular Medicine.

[27]  Theresa M. Harrison,et al.  An Alzheimer’s Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults , 2016, eNeuro.

[28]  R. Buckner,et al.  Polygenic risk of Alzheimer disease is associated with early- and late-life processes , 2016, Neurology.

[29]  Amelia A. Assareh,et al.  The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume , 2016, Neurobiology of Aging.

[30]  A. Hofman,et al.  Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[31]  Sonja W. Scholz,et al.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases , 2017, Neurobiology of Aging.

[32]  Nick C Fox,et al.  Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease , 2017, Nature Genetics.

[33]  D. Schaid,et al.  Polygenic risk scores in familial Alzheimer disease , 2017, Neurology.

[34]  Lilah M. Besser,et al.  Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score , 2017, PLoS medicine.

[35]  R. Sims,et al.  The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[36]  J. Hardy,et al.  Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease , 2017, Neurobiology of Aging.

[37]  Yunxia Jiang,et al.  Association between apolipoprotein E gene polymorphism and mild cognitive impairment: a meta-analysis , 2017, Clinical interventions in aging.

[38]  A. Myers,et al.  Polygenic risk score analysis of pathologically confirmed Alzheimer disease , 2017, Annals of neurology.

[39]  Lilah M. Besser,et al.  Polygenic hazard scores in preclinical Alzheimer’s disease , 2017, bioRxiv.

[40]  K. Morgan,et al.  Genotyping of the Alzheimer's Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort. , 2018, Journal of Alzheimer's disease : JAD.

[41]  D. Hernandez,et al.  Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease , 2018, Neurobiology of Aging.

[42]  P. Francis,et al.  Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value , 2018, Journal of Alzheimer's disease : JAD.

[43]  E. Topol,et al.  The personal and clinical utility of polygenic risk scores , 2018, Nature Reviews Genetics.

[44]  H. Hakonarson,et al.  Polygenic Risk Score for Alzheimer's Disease: Implications for Memory Performance and Hippocampal Volumes in Early Life. , 2018, The American journal of psychiatry.

[45]  O. Andreassen,et al.  Use of an Alzheimer’s disease polygenic risk score to identify mild cognitive impairment in adults in their 50s , 2019, Molecular Psychiatry.